Back

Immune responses in pancreatic cancer may be restricted byprevalence of activated regulatory T-cells, dysfunctionalCD8+ T-cells, and senescent T-cells

Sivakumar, S.; Abu-Shah, E.; Ahern, D.; Arbe-Barnes, E. H.; Mangal, N.; Reddy, S.; Rendek, A.; Easton, A.; Kurz, E.; Silva, M.; Heij, L. R.; Soonawalla, Z.; Bashford-Rogers, R.; Middleton, M. R.; Dustin, M.

2020-06-20 immunology
10.1101/2020.06.20.163071 bioRxiv
Show abstract

Pancreatic cancer has the worst prognosis of any human malignancy and leukocyte infiltration is a major prognostic marker of the disease. As current immunotherapies confer negligible survival benefits, there is a need to better characterise leukocytes in pancreatic cancer to identify better therapeutic strategies. In this study, we analysed 32 human pancreatic cancer patients from two independent cohorts. A multi-parameter mass-cytometry analysis was performed on 32,000 T-cells from eight patients. Single-cell RNA sequencing dataset analysis was performed on a cohort of 24 patients. Multiplex immunohistochemistry imaging and spatial analysis were performed to map immune infiltration into the tumour microenvironment. Regulatory T-cell populations demonstrated highly immunosuppressive states with high TIGIT, ICOS and CD39 expression. CD8+ T-cells were found to be either in senescence or an exhausted state. The exhausted CD8 T-cells had low PD-1 expression but high TIGIT and CD39 expression. These findings were corroborated in an independent pancreatic cancer single-cell RNA dataset from additional 24 patients. These data suggest that T-cells are major players in the suppressive microenvironment of pancreatic cancer. Our work identifies novel therapeutic targets that should form the basis for rational design of a new generation of clinical trials in pancreatic ductal adenocarcinoma.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
European Journal of Immunology
60 papers in training set
Top 0.1%
22.4%
2
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.2%
10.0%
3
Frontiers in Immunology
638 papers in training set
Top 2%
8.0%
4
Nature Communications
5641 papers in training set
Top 22%
7.4%
5
Science Immunology
88 papers in training set
Top 0.5%
5.3%
50% of probability mass above
6
eLife
5828 papers in training set
Top 37%
2.8%
7
Science Advances
1243 papers in training set
Top 12%
2.8%
8
OncoImmunology
24 papers in training set
Top 0.2%
2.8%
9
Communications Biology
993 papers in training set
Top 12%
1.9%
10
Gut
40 papers in training set
Top 0.5%
1.8%
11
Cancer Immunology Research
35 papers in training set
Top 0.5%
1.8%
12
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.3%
1.8%
13
Nature Immunology
79 papers in training set
Top 1%
1.8%
14
EMBO Molecular Medicine
95 papers in training set
Top 0.9%
1.7%
15
Cancer Discovery
66 papers in training set
Top 1%
1.5%
16
The Journal of Pathology
26 papers in training set
Top 0.5%
1.2%
17
Genome Medicine
183 papers in training set
Top 4%
1.2%
18
npj Precision Oncology
53 papers in training set
Top 1%
1.1%
19
Clinical Cancer Research
64 papers in training set
Top 2%
1.1%
20
Cell Reports Medicine
153 papers in training set
Top 4%
0.9%
21
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 39%
0.9%
22
Scientific Reports
3612 papers in training set
Top 72%
0.9%
23
Cell Reports
1498 papers in training set
Top 26%
0.9%
24
Cancer Research
130 papers in training set
Top 3%
0.9%
25
Life Science Alliance
285 papers in training set
Top 8%
0.6%
26
iScience
1154 papers in training set
Top 38%
0.6%
27
Journal of Clinical Investigation
179 papers in training set
Top 6%
0.6%
28
Molecular Oncology
55 papers in training set
Top 1%
0.6%